DK157859C - Analogifremgangsmaade til fremstilling af oxoquinolin-3-carboxamider - Google Patents

Analogifremgangsmaade til fremstilling af oxoquinolin-3-carboxamider

Info

Publication number
DK157859C
DK157859C DK081282A DK81282A DK157859C DK 157859 C DK157859 C DK 157859C DK 081282 A DK081282 A DK 081282A DK 81282 A DK81282 A DK 81282A DK 157859 C DK157859 C DK 157859C
Authority
DK
Denmark
Prior art keywords
preparation
carboxamides
oxoquinolin
analogy procedure
analogy
Prior art date
Application number
DK081282A
Other languages
Danish (da)
English (en)
Other versions
DK81282A (da
DK157859B (da
Inventor
Edgar Eriksoo
Britt-Marie Sandberg
Torbjoern Staalhandske
Original Assignee
Leo Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Ab filed Critical Leo Ab
Publication of DK81282A publication Critical patent/DK81282A/da
Publication of DK157859B publication Critical patent/DK157859B/da
Application granted granted Critical
Publication of DK157859C publication Critical patent/DK157859C/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK081282A 1981-03-03 1982-02-24 Analogifremgangsmaade til fremstilling af oxoquinolin-3-carboxamider DK157859C (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8106594 1981-03-03
GB8106594 1981-03-03

Publications (3)

Publication Number Publication Date
DK81282A DK81282A (da) 1982-09-04
DK157859B DK157859B (da) 1990-02-26
DK157859C true DK157859C (da) 1990-07-30

Family

ID=10520089

Family Applications (1)

Application Number Title Priority Date Filing Date
DK081282A DK157859C (da) 1981-03-03 1982-02-24 Analogifremgangsmaade til fremstilling af oxoquinolin-3-carboxamider

Country Status (21)

Country Link
US (2) US4547511A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0059698B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS57171975A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR860001876B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE15798T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU547849B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1182455A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE3266464D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK157859C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES8400409A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI79532C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR76073B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK38689A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU186909B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE52670B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL65028A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO163130C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ199888A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH18520A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT74512B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA821210B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3269753A (en) * 1964-08-31 1966-08-30 Data Man Inc Bookkeeping unit
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
US4400017A (en) * 1981-03-04 1983-08-23 Pendergrass Russell G Integrated budget and check record book
US4650804A (en) * 1984-03-30 1987-03-17 Fujisawa Pharmaceutical Co., Ltd. Quinolizinone compounds and pharmaceutical composition comprising the same, useful as anti-ulcerative and anti-allergic agents
DE3420116A1 (de) * 1984-05-30 1985-12-05 Bayer Ag, 5090 Leverkusen Immunstimulierende mittel
US4786644A (en) * 1987-11-27 1988-11-22 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-quinolinecarboxamide
IT1228293B (it) * 1989-02-06 1991-06-07 Angeli Inst Spa Benzoderivati di composti eterociclici contenenti azoto.
US5310913A (en) * 1989-06-09 1994-05-10 Kabi Pharmacia Aktiebolag Derivatives of quinoline-3-carboxanilide
SE8902076D0 (sv) * 1989-06-09 1989-06-09 Pharmacia Ab Derivatives of quinoline-3-carboxanilide
US5691350A (en) * 1990-02-22 1997-11-25 Kabi Pharmacia Ab Use of linomide for treatment of retrovirus infections specifically HIV infections
SE9000624D0 (sv) * 1990-02-22 1990-02-22 Pharmacia Ab New use
US5504092A (en) * 1990-03-27 1996-04-02 Pharmacia Ab Use of Linomide to increase hemopoietic cell precursors
SE9001111D0 (sv) * 1990-03-27 1990-03-27 Pharmacia Ab Supportive use
US5412104A (en) * 1990-09-07 1995-05-02 Schering Corporation Ester and alkoxy substituted benzopyrans
AU8448491A (en) * 1990-09-07 1992-03-30 Schering Corporation Antiviral compounds and antihypertensive compounds
AU8612491A (en) * 1990-09-07 1992-03-30 Schering Corporation Antiviral compounds
US5219864A (en) * 1991-03-12 1993-06-15 Kyowa Hakko Kogyo Co., Ltd. Thienopyridine derivatives
GB9108547D0 (en) * 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
SE469368B (sv) * 1991-10-09 1993-06-28 Kabi Pharmacia Ab Ny anvaendning av linomide foer tillverkning av laekemedel foer behandling av multiple sclerosis (ms)
TW222276B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1992-01-27 1994-04-11 Fujisawa Pharmaceutical Co
SE9201076L (sv) * 1992-04-06 1993-10-07 Shimon Slavin Användningen av gamla läkemedel för behandling av diabetes
GB9311562D0 (en) * 1993-06-04 1993-07-21 Fujisawa Pharmaceutical Co Heterocyclic derivatives
SE9302490D0 (sv) * 1993-07-26 1993-07-26 Kabi Pharmacia Ab New use of old drugs
GB9404378D0 (en) * 1994-03-07 1994-04-20 Fujisawa Pharmaceutical Co Quinoline derivatives
SE9400810D0 (sv) * 1994-03-10 1994-03-10 Pharmacia Ab New use of Quinoline-3-carboxamide compounds
SE9400809D0 (sv) * 1994-03-10 1994-03-10 Pharmacia Ab New use of quinoline-3-carboxamide compounds
CN1215835C (zh) * 1996-03-27 2005-08-24 东丽株式会社 酮衍生物及其在医学上的应用
US5912349A (en) * 1997-01-31 1999-06-15 Pharmacia & Upjohn Company Process for the preparation of roquinimex
JPH1171351A (ja) * 1997-08-29 1999-03-16 Ss Pharmaceut Co Ltd 置換キノロン誘導体及びこれを含有する医薬
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6133285A (en) 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
SE9802549D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
JP2000044561A (ja) * 1998-07-31 2000-02-15 Kyorin Pharmaceut Co Ltd ピロロキノリン誘導体及びその製造方法
JP2000044560A (ja) * 1998-07-31 2000-02-15 Kyorin Pharmaceut Co Ltd ベンゾキノリジン誘導体及びその製造方法
JP2000256323A (ja) 1999-01-08 2000-09-19 Japan Tobacco Inc ２−オキソキノリン化合物及びその医薬用途
SE0002320D0 (sv) * 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
PL199781B1 (pl) 1999-10-25 2008-10-31 Active Biotech Ab Nowe związki pochodne chinoliny, zastosowanie związków pochodnych chinoliny, zawierające je kompozycje farmaceutyczne i sposób ich wytwarzania
RU2240313C2 (ru) * 1999-10-25 2004-11-20 Эктив Байотек Аб Лекарственные средства для лечения злокачественных опухолей
AU1302301A (en) * 1999-11-08 2001-06-06 Sankyo Company Limited Nitrogenous heterocycle derivatives
US6525049B2 (en) 2000-07-05 2003-02-25 Pharmacia & Upjohn Company Pyrroloquinolones as antiviral agents
JP2003012667A (ja) * 2001-06-26 2003-01-15 Rrf Kenkyusho:Kk キノリンカルボキサミド骨格を有する抗菌剤
US6822097B1 (en) * 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
US7560557B2 (en) * 2002-06-12 2009-07-14 Active Biotech Ag Process for the manufacture of quinoline derivatives
SE0201778D0 (sv) * 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
US6875869B2 (en) * 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
ES2423800T3 (es) 2003-03-28 2013-09-24 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos orgánicos para la inmunopotenciación
WO2004104000A1 (ja) * 2003-05-23 2004-12-02 Japan Tobacco Inc. トリサイクリック縮合環化合物およびその医薬用途
SE0400235D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
US8314124B2 (en) * 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
EP1765313A2 (en) 2004-06-24 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
US7228698B2 (en) * 2005-06-30 2007-06-12 Premark Feg L.L.C. Refrigeration unit
WO2007038571A2 (en) * 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
CA2625287C (en) * 2005-10-19 2016-07-26 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium, and process for the manufacture thereof
US7728130B2 (en) * 2005-12-09 2010-06-01 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity
WO2007124617A1 (fr) * 2006-04-28 2007-11-08 Institute Of Mataria Medica, Chinese Academy Of Medical Sciences Dérivés de coumarine, leurs procédés de préparation, compositions pharmaceutiques et utilisations
PL2035001T3 (pl) 2006-06-12 2012-05-31 Teva Pharmaceutical Industries Ltd Stabilne preparaty lakwinimodu
EP2977049A1 (en) * 2007-12-20 2016-01-27 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
US8552194B2 (en) * 2008-04-28 2013-10-08 Actavis Group Ptc Ehf Process for preparing quinoline-3-carboxamide derivatives
WO2010028015A2 (en) * 2008-09-03 2010-03-11 Auspex Pharmaceuticals, Inc 2-oxo-1,2-dihydro-quinoline modulators of immune function
DK2349263T3 (da) 2008-10-23 2014-07-21 Vertex Pharma Modulatorer af transmembranledningsevneregulatoren for cystisk fibrose
WO2010059549A1 (en) * 2008-11-18 2010-05-27 Glaxosmithkline Llc Prolyl hydroxylase inhibitors
EP2376456A2 (en) * 2008-12-17 2011-10-19 Actavis Group Ptc Ehf Highly pure laquinimod or a pharmaceutically acceptable salt thereof
KR20120045032A (ko) * 2009-07-30 2012-05-08 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드를 이용한 크론병의 치료
HUE029983T2 (en) * 2009-08-10 2017-04-28 Teva Pharma Treatment of BDNF-related diseases with laquinimod
AU2011223697B2 (en) * 2010-03-03 2016-07-14 Teva Pharmaceutical Industries Ltd. Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
PT2542080T (pt) * 2010-03-03 2016-11-16 Teva Pharma Tratamento de artrite causada por lúpus usando laquinimod
EP2542078B1 (en) * 2010-03-03 2015-10-07 Teva Pharmaceutical Industries Ltd. Treatment of lupus nephritis using laquinimod
NZ606589A (en) * 2010-07-09 2015-03-27 Teva Pharma 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof
JP2013535437A (ja) 2010-07-09 2013-09-12 テバ ファーマシューティカル インダストリーズ リミティド 重水素化されたｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４−ヒドロキシ−５−クロロ−１−メチル−２−オキソキノリン−３−カルボキサミド、その塩および使用
MX2013004169A (es) * 2010-10-14 2013-06-05 Immunahr Ab 1, 2-dihidro-4-hidroxi-2-oxo-quinolina-3-carboxanilidas como activadores del receptor de hidrocarburo aromatico.
FR2967353B1 (fr) * 2010-11-16 2013-08-16 Centre Nat Rech Scient Derives de quinolinone
FR2967498B1 (fr) * 2010-11-16 2015-01-02 Centre Nat Rech Scient Utilisation de derives de quinolinone comme outil de recherche
HK1199820A1 (en) 2011-10-12 2015-07-24 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
EP2780013A4 (en) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
US9206128B2 (en) 2011-11-18 2015-12-08 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
JP2015505564A (ja) 2012-02-03 2015-02-23 テバ ファーマシューティカル インダストリーズ リミティド 第一選択の抗ＴＮＥα療法に失敗したクローン病患者を治療するためのラキニモドの使用
NZ628762A (en) 2012-02-10 2016-07-29 Constellation Pharmaceuticals Inc Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013123419A1 (en) 2012-02-16 2013-08-22 Teva Pharmaceutical Industries Ltd. N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
WO2014074381A1 (en) 2012-11-07 2014-05-15 Teva Pharmaceutical Industries Ltd. Amine salts of laquinimod
CA2901849A1 (en) 2013-03-14 2014-09-25 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP3033334A1 (en) 2013-08-15 2016-06-22 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
HK1231413A1 (zh) 2014-04-29 2017-12-22 Teva Pharmaceutical Industries Ltd. 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德
WO2017040190A1 (en) 2015-08-28 2017-03-09 Constellation Pharmaceuticals, Inc. Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide
CN109843870A (zh) 2016-10-19 2019-06-04 星座制药公司 Ezh2抑制剂的合成
GB202006390D0 (en) 2020-04-30 2020-06-17 Aqilion Ab Novel treatments
CN115836056A (zh) * 2020-05-21 2023-03-21 Stemsynergy疗法有限责任公司 Notch抑制剂及其用途
CN111732540B (zh) * 2020-07-20 2020-11-13 湖南速博生物技术有限公司 一种罗喹美克的制备方法
AR126963A1 (es) 2021-09-13 2023-12-06 Lilly Co Eli Agonistas de ahr
TWI838849B (zh) 2021-09-13 2024-04-11 美商美國禮來大藥廠 Ahr促效劑
CN120435469A (zh) 2022-10-31 2025-08-05 伊莱利利公司 Ahr激动剂
KR20250083557A (ko) 2022-11-15 2025-06-10 일라이 릴리 앤드 캄파니 Ahr 효능제

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH471784A (de) * 1966-01-26 1969-04-30 Bayer Ag Verfahren zur Herstellung von Carbostyrilderivaten
US3524858A (en) * 1967-05-18 1970-08-18 Warner Lambert Pharmaceutical 1,4 - dihydro-1-substituted alkyl-6,7-methylenedioxy - 4 - oxoquinoline-3-carboxylic acid
CH578534A5 (en) 1973-05-11 1976-08-13 Ciba Geigy Ag Quinoline-3-carboxylic acid derivs - with e.g. analgesic, antinociceptive, antiinflammatory and antiallergic props
CH578537A5 (en) 1973-05-11 1976-08-13 Ciba Geigy Ag Quinoline-3-carboxylic acid derivs - with e.g. analgesic, antinociceptive, antiinflammatory and antiallergic props
CH578535A5 (en) 1973-05-11 1976-08-13 Ciba Geigy Ag Quinoline-3-carboxylic acid derivs - with e.g. analgesic, antinociceptive, antiinflammatory and antiallergic props
CH578536A5 (en) 1973-05-11 1976-08-13 Ciba Geigy Ag Quinoline-3-carboxylic acid derivs - with e.g. analgesic, antinociceptive, antiinflammatory and antiallergic props
CA1034124A (en) * 1973-05-11 1978-07-04 Ciba-Geigy Ag Process for the manufacture of new quinolines
US3917609A (en) * 1973-06-27 1975-11-04 Minnesota Mining & Mfg Pyrroloquinoline carboxylic acids and derivatives
FR2281761A1 (fr) * 1974-08-13 1976-03-12 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
FR2340735A1 (fr) * 1976-02-11 1977-09-09 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
FR2482596A1 (fr) * 1980-05-19 1981-11-20 Roussel Uclaf Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur procede de preparation et leur application comme medicament
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation

Also Published As

Publication number Publication date
ES510042A0 (es) 1983-10-16
FI79532C (fi) 1990-01-10
AU547849B2 (en) 1985-11-07
IE52670B1 (en) 1988-01-20
NO163130B (no) 1990-01-02
JPS57171975A (en) 1982-10-22
IE820314L (en) 1982-09-03
FI820728L (fi) 1982-09-04
KR860001876B1 (ko) 1986-10-24
PH18520A (en) 1985-08-02
US4738971A (en) 1988-04-19
JPH049786B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1992-02-21
DK81282A (da) 1982-09-04
HU186909B (en) 1985-10-28
NO820642L (no) 1982-09-06
KR830009037A (ko) 1983-12-17
FI79532B (fi) 1989-09-29
GR76073B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1984-08-03
EP0059698B1 (en) 1985-09-25
IL65028A (en) 1986-11-30
CA1182455A (en) 1985-02-12
PT74512B (en) 1983-11-08
PT74512A (en) 1982-04-01
HK38689A (en) 1989-05-19
DE3266464D1 (en) 1985-10-31
NO163130C (no) 1990-04-11
AU8107682A (en) 1982-09-09
ATE15798T1 (de) 1985-10-15
DK157859B (da) 1990-02-26
EP0059698A1 (en) 1982-09-08
ZA821210B (en) 1983-01-26
IL65028A0 (en) 1982-04-30
ES8400409A1 (es) 1983-10-16
US4547511A (en) 1985-10-15
NZ199888A (en) 1985-07-31

Similar Documents

Publication Publication Date Title
DK157859C (da) Analogifremgangsmaade til fremstilling af oxoquinolin-3-carboxamider
DK162770C (da) Analogifremgangsmaade til fremstilling af 3,20-dioxo-1,4-pregnadien-17alfa-ol-17-heteroaromatiske carboxylater
DK163145C (da) Analogifremgangsmaade til fremstilling af 6-substituerede s-triazoloe3,4-aaaftalazin-derivater
DK166280C (da) Analogifremgangsmaade til fremstilling af terapeutisk aktive 2-azetidinoner
IT8220946A0 (it) Procedimento per preparare composizioni di enzimi coagulanti del sangue
NO821198L (no) Fremgangsmaate for fremstilling av preparater for behandling av melanomer.
DK162389C (da) Analogifremgangsmaade til fremstilling af 2-oe4-oe(4,4-dialkyl-2,6-piperidindion-1-yl)butylaa-1-piperazinylaapyrimidiner
DK453681A (da) Fremgangsmaade til behandling af tobak
IS1307B6 (is) Aðferð til að framleiða lyfjablöndu
NO152551C (no) Fremgangsmaate til fremstilling av rent silisium.
DK152493C (da) Analogifremgangsmaade til fremstilling af hydroxypropyl-triazoler
DK465481A (da) Fremgangsmaade til fremstilling af d-homostemoider
SE8300912D0 (sv) Kompositioner for behandling av glaukom
DK550586D0 (da) Laegemiddel til behandling af neuropsykiatriske tilstande, saasom demens
NO154492C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme forbindelser.
IT1194748B (it) Composizioni farmaceutiche per il trattamento di osteopatie
DK267979A (da) Fremgangsmaade til fremstilling af aryloxypropanolaminer
DK280282A (da) Fremgangsmaade til fremstilling af farmaceutiske praeparater indeholdende ergotalkaloider
DK427281A (da) Fremgangsmaade til fremstilling af terapeutiske praeparater
ATE11013T1 (de) Heilmittelzusammensetzungen zur behandlung der haut.
SE8300913D0 (sv) Kompositioner for behandling av glaukom
DK361282A (da) Fremgangsmaade til fremstilling af o-alkyl-o-carbamoylglycerophosphocholiner
DK149748C (da) Analogifremgangsmaade til fremstilling af n-phenethylacetamidforbindelser
NO154632C (no) Analogifremgangsmaate til fremstilling av pyrolidinderivater.
NO154494C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive fluorprostacykliner.

Legal Events

Date Code Title Description
PBP Patent lapsed